# Acute hYpErcapnic respiratory failure in The ICU: A multicenter prospective observational study - The YETI study

**Authors:** Claire Dupuis, Toufik Kamel, Christophe Beyls, Charlène Le Moal, Pierre Garcon, Suzanne Goursaud, Laetitia Bodet-Contentin, Alexis Ferré, Max Guillot, Alexandre Gachet, Thibaut Noel, Aude Garin, Laurent Argaud, Konstantinoss Bachoumas, Romain Persichini, Maud Jonas, Mai-Anh Nay, Cyril Cadoz, Frédérique Schortgen, Solène Guinard, Camille Foucault, Guylaine Labro, Jean-François Llitjos, Anahita Rouze, Tài Pham, Bertrand Hermann

PMC · DOI: 10.1016/j.aicoj.2025.100016 · Annals of Intensive Care · 2026-01-16

## TL;DR

This study found that about 5% of ICU patients have acute hypercapnic respiratory failure, often due to chronic lung diseases and infections, with specific risk factors for severe outcomes.

## Contribution

The study provides new large-scale epidemiological data on acute hypercapnic respiratory failure in ICU patients across multiple centers.

## Key findings

- AHcRF prevalence was 4.9% among ICU admissions and 12.5% among acute respiratory failure cases.
- Chronic obstructive pulmonary disease and infections were the main causes of AHcRF.
- Non-invasive ventilation was used in 81.3% of cases, but 35.9% required invasive ventilation.

## Abstract

Acute hypercapnic respiratory failure (AHcRF) is a common cause of intensive care unit (ICU) admission, particularly in patients with chronic respiratory diseases. However, large-scale epidemiological data on AHcRF prevalence, management, and outcomes in the ICU remain limited.

The YETI (Acute hYpErcapnic respiratory failure in The ICU) study was a prospective, multicenter, observational study conducted across 58 ICUs in France and Belgium between December 2021 and June 2022. Adult patients admitted with AHcRF (PaCO₂ > 45 mmHg and clinical signs of respiratory failure) were enrolled. The primary outcome was the prevalence of AHcRF among all ICU admissions. Secondary outcomes included etiologies, management strategies and factors associated with intubation and mortality.

Among 20,482 ICU admissions, 1,010 patients presented AHcRF, and 856 met inclusion criteria. The prevalence for AHcRF among all critically ill patients was 4.9% [95% CI: 4.6, 5.2], and among ICU patients admitted for acute respiratory failure, it was 12.5% [95 % CI: 11.8, 13.2]. Most patients had underlying obstructive lung diseases (Chronic Obstructive Pulmonary Disease: 56.3%; Obstructive Sleep Apnea Syndrome: 18.5%). Infection (52.2%) and cardiogenic pulmonary edema (15.4%) were the most frequent causes for respiratory failure. Non-invasive ventilation (NIV) was used in 81.3% of patients and 35.9% received invasive mechanical ventilation, mainly for coma or NIV failure. ICU mortality was 12.7%. Multivariable analysis identified lower pH, lower Glasgow Coma Scale, infectious etiology, and higher SOFA (Sequential Organ Failure Assessment) score as independent predictors of intubation. ICU mortality was associated with older age, lower body mass index, active cancer, and higher SOFA scores.

Ten percent of patients admitted to the ICU with respiratory failure present AHcRF, primarily driven by chronic obstructive diseases and infections. Despite widespread NIV use, one-third of patients were treated with invasive ventilation. Identifying risk factors for invasive mechanical ventilation and mortality may support earlier triage and personalized management strategies.

## Linked entities

- **Diseases:** Chronic Obstructive Pulmonary Disease (MONDO:0005002), Obstructive Sleep Apnea Syndrome (MONDO:0007147)

## Full-text entities

- **Diseases:** Coma (MESH:D003128), drug overdose (MESH:D062787), chronic (MESH:D002908), OHS (MESH:D010845), neuromuscular diseases (MESH:D009468), sleep apnea (MESH:D012891), pathologies (MESH:D005598), heart disease (MESH:D006331), OSAS (MESH:D020181), heart failure (MESH:D006333), NIV (MESH:D000093284), acid-base disturbances (MESH:D000137), acidosis (MESH:D000138), obstructive lung diseases (MESH:D008173), Infection (MESH:D007239), Cardiovascular conditions (MESH:D002318), COVID-19 (MESH:D000086382), immune dysfunction (MESH:D007154), chronic renal failure (MESH:D007676), hypertension (MESH:D006973), impaired consciousness (MESH:D003244), death (MESH:D003643), GOLD 3 or 4 (MESH:D053307), hypoxemia (MESH:D000860), IMV (MESH:D053717), metabolic disorders (MESH:D008659), Acute (MESH:D000208), Pulmonary Embolism (MESH:D011655), COPD (MESH:D029424), Pneumonia (MESH:D011014), hypercapnia (MESH:D006935), Acute Hypercapnic Respiratory Failure (MESH:D012131), pleural effusion (MESH:D010996), Organ Failure (MESH:D009102), ACOS (MESH:D000080445), Obesity (MESH:D009765), smoking (MESH:D015208), ACPE (MESH:D011654), asthma (MESH:D001249), NIV failure (MESH:D051437), diabetes (MESH:D003920), lung diseases (MESH:D008171), cancer (MESH:D009369), respiratory disease (MESH:D012140), chronic obstructive respiratory comorbidities (MESH:D012142), nocturnal hypoventilation (MESH:D007040), trauma (MESH:D014947), respiratory infections (MESH:D012141), critically ill (MESH:D016638)
- **Chemicals:** CD (MESH:D002104), Hydrogen (MESH:D006859), CO2 (MESH:D002245), steroids (MESH:D013256), Bicarbonate (MESH:D001639), Beta-2 agonists (-), O2 (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12934414/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12934414/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12934414/full.md

---
Source: https://tomesphere.com/paper/PMC12934414